Heterocyclic Scaffolds in PARP-1 Inhibition: An Emerging Strategy for Targeted Anticancer Therapy.

Zejula (niraparib) - GSK, J&J

Rubraca (rucaparib) - Pharma& Schweiz

Lynparza (olaparib) - Merck (MSD), AstraZeneca

Talzenna (talazoparib) - Pfizer

http://www.ncbi.nlm.nih.gov/pubmed/42634307

Gowramma Byran; Hardha Balachandran; Kalirajan Rajagopal; Senthil Kumar Murugesan; Veera Venkata Satyanarayana Reddy Karri

Aug 25, 2026